A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

References

• Sobel JD. Practice guidelines for the treatment of fungal infections. Clin Infect Dis 2000; 30: 652.
   PubMed Web of Science ®Google Scholar
• Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the post mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23–32.
   Google Scholar
• Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, et al. Guidelines for the investigation of invasive fungal infections in hematological malignancy and solid organ transplantation. Eur J Clin Microbiol Infect Dis 1997; 16: 424–36.
   PubMed Web of Science ®Google Scholar
• Denning DW Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–15.
   PubMed Web of Science ®Google Scholar
• Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677–88.
   PubMed Web of Science ®Google Scholar
• Fishman J, Rubin RH. Fungal infection in the organ transplant recipient. Infect Dis Clin 1998; Pract 7 (Suppl 1): S42–8.
   Google Scholar
• Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653–7.
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 y of clinical experience. Rev Infect Dis 1990; 12: 308–29.
   Google Scholar
• British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. Lancet 1991; 337: 1577–80.
   PubMed Web of Science ®Google Scholar
• Mujisers RBR, Goa KL, Scott LJ. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002; 62: 2655–64.
   Google Scholar
• Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915–28.
   PubMed Web of Science ®Google Scholar
• Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61: 1121–9.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin vs amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529–35.
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Anti- microb Agents Chemother 2000; 44: 57–62.
   PubMed Web of Science ®Google Scholar
• Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, Tawara S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614–8.
   PubMed Web of Science ®Google Scholar
• Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S. Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000; 44: 1728–30.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44: 619–21.
   PubMed Web of Science ®Google Scholar
• Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662–78.
   PubMed Web of Science ®Google Scholar
• Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696–709.
   PubMed Web of Science ®Google Scholar
• Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993; 31: 463–71.
   PubMed Web of Science ®Google Scholar
• Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1993; 39: 1–8.
   Google Scholar
• Anaissie EJ, Rex JH, Uzun Ö, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238–45.
   Google Scholar
• Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692–6.
   PubMed Web of Science ®Google Scholar
• de Marie S, Janknegt R, Bakker-Woundenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907–16.
   Google Scholar
• Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001; 35: 720–9.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15.
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–71.
   PubMed Web of Science ®Google Scholar
• Ally R, Shürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized, double-blined, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromized patients. Clin Infect Dis 2001; 33: 1447–54.
   PubMed Web of Science ®Google Scholar
• Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982; 61: 109–24.
   Google Scholar
• Gefter WB. The spectrum of pulmonary aspergillosis. J Thorac Imaging 1992; 7(4): 56–74.
   PubMed Web of Science ®Google Scholar
• Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7(Suppl 2): 25–31.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromized patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
   PubMed Web of Science ®Google Scholar
• Van Burik J, Ratanatharathorn V, Lipton J, Miller C, Bunin N, Walsh TJ. Randomized, double-blind trial of micafungin vs fluconazole for prophylaxis of invasive fungal infections in patients undergoing haematopoetic stem cell transplant. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27–30, 2002, San Diego, USA: 401(abstr M–1238).
   Google Scholar
• De Wet NTE, Llanos-Cuentas A, Suleiman H, Baraldi E, Krantz E, Della Negra M, Diekmann-Berndt H. Micafungin (FK463) dose response and comparison with fluconazole in esophageal candidasis. Program and abstracts of the 43rd Interrscience Conference on Antimicrobial Agents and Chemotherapy; Sept 14–17, 2003, Chicago, USA: 476 (abstr M–1754)
   Google Scholar